Goldman Sachs
TOVX icon

Goldman Sachs’s Theriva Biologics TOVX Stock Holding History

Goldman Sachs’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-268
Closed -$30K – 5408
2019
Q3 		$30K Buy
268
+223
+496% +$26.9K ﹤0.01% 5083
2019
Q2 		$6K Hold
45
– – ﹤0.01% 5090
2019
Q1 		$8K Buy
+45
New +$7.45K ﹤0.01% 5071
2017
Q3 		– Sell
-129
Closed -$639K – 6860
2017
Q2 		$639K Buy
129
+127
+6,350% +$633K ﹤0.01% 4875
2017
Q1 		$9K Buy
+2
New +$14K ﹤0.01% 6623
2016
Q4 		– Sell
-3
Closed -$48K – 7091
2016
Q3 		$48K Buy
3
+2
+200% +$29.9K ﹤0.01% 6489
2016
Q2 		$20K Sell
1
-11
-92% -$207K ﹤0.01% 6721
2016
Q1 		$249K Buy
12
+9
+300% +$135K ﹤0.01% 5419
2015
Q4 		$57K Buy
+3
New +$63.5K ﹤0.01% 6474
2015
Q2 		– Sell
-3
Closed -$55K – 7438
2015
Q1 		$55K Buy
3
+2
+200% +$35.7K ﹤0.01% 6660
2014
Q4 		$19K Sell
1
-4
-80% -$53.7K ﹤0.01% 6993
2014
Q3 		$84K Sell
5
-1
-17% -$16.3K ﹤0.01% 6656
2014
Q2 		$86K Hold
6
– – ﹤0.01% 6611
2014
Q1 		$129K Buy
6
+2
+50% +$41.4K ﹤0.01% 6302
2013
Q4 		$50K Buy
+4
New +$50.5K ﹤0.01% 6424

Other funds holding TOVX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs's TOVX Position: Q4 2019 in Review

Goldman Sachs sold out of Theriva Biologics (TOVX) in Q4 2019, closing a stake of 268 shares — an estimated $30K sold.

Goldman Sachs first reported a position in TOVX in Q4 2013 and held it in 15 quarters. The position peaked at $639K in Q2 2017. 17 funds tracked by Wall St. Rank hold TOVX as of Q4 2019.

  • Goldman Sachs reported no remaining Theriva Biologics position as of Q4 2019 after selling out during the quarter.
  • Goldman Sachs sold 268 Theriva Biologics shares in Q4 2019, an estimated $30K.
  • Goldman Sachs first reported a position in Theriva Biologics in Q4 2013 and held it in 15 quarters.
  • Goldman Sachs's Theriva Biologics position peaked at $639K in Q2 2017.
  • 17 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2019.

Based on Goldman Sachs's 13F filing for Q4 2019, filed 14 Feb 2020.